3.8 Article

Patient-reported outcomes are the strongest predictors of disease disability in intramuscular interferon beta-1a users

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Clinical Neurology

Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium

Caila B. Vaughn et al.

MULTIPLE SCLEROSIS JOURNAL (2020)

Review Pharmacology & Pharmacy

Long-term drug treatment in multiple sclerosis: safety success and concerns

Dejan Jakimovski et al.

EXPERT OPINION ON DRUG SAFETY (2020)

Article Medicine, Research & Experimental

Interferon β for Multiple Sclerosis

Dejan Jakimovski et al.

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)

Article Medicine, General & Internal

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

S. L. Hauser et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Review Biotechnology & Applied Microbiology

Clinical, MRI, and CSF Markers of Disability Progression in Multiple Sclerosis

Alberto Gajofatto et al.

DISEASE MARKERS (2013)

Article Health Care Sciences & Services

Potential of patient-reported outcomes as nonprimary endpoints in clinical trials

Ari Gnanasakthy et al.

HEALTH AND QUALITY OF LIFE OUTCOMES (2013)

Review Clinical Neurology

Benign Multiple Sclerosis: Does it exist?

Jorge Correale et al.

CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2012)